Osteoarthritis, colloquially known as “wear-and-tear arthritis”, is the most common form of arthritis, frequently affecting the joints of the hands, feet, knees, hips and spine. It involves degeneration of articular cartilage, which exposes the underlying subchondral bone, resulting in sclerosis and subsequent bone remodelling which ultimately leads to a narrowing of the joint space.
Pain and loss of function are the hallmark symptoms of osteoarthritis. Swelling and stiffness of the affected joint is often apparent, with enlargement of the fingers around the interphalangeal joints particularly common where the hands are affected.
First-line treatment for osteoarthritis involves non-pharmacological methods, with a particular focus on education and encouraging weight loss among overweight patients. This may be supplemented with analgesics and NSAIDs as required. In some cases, intra-articular corticosteroid injections provide short term pain relief, and where conservative therapy proves ineffectual, surgery may also be considered.
To find out more about Osteoarthritis, visit our dedicated Learning Zone, which contains further information on the management of this condition.
Latest Clinical Guidelines, Trials and Journals
This study attempts to observe the effectiveness and safety of aripiprazole in hospitalized patients with acute schizophrenia episode, and to compare the different drug regimens that may be involved in order to clarify the characteristics...
These updated guidelines on the management of variceal haemorrhage have been commissioned by the Clinical Services and Standards Committee (CSSC) of the British Society of Gastroenterology (BSG) under the auspices of the liver section of the BSG.
Latest news and insights
A new retrospective data analysis published in Kidney Medicine shows that a higher percentage of hemodialysis patients prescribed Velphoro (sucroferric oxyhydroxide chewable tablets), from Fresenius Medical, achieved target serum phosphorous levels of less than or equal to 5.5 mg/dL compared to those patients who
Takeda Pharmaceutical Co announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with CHP (cyclophosphamide,
Novo Nordisk announced that the New England Journal of Medicine published results of a phase III trial evaluating the investigational use of Saxenda (liraglutide) injection 3.0 mg in adolescents (aged 12– 18) with obesity.